Pharmaceutical Development and Technology 2014-11-01

Influence of the type of vegetable oil on the drug release profile from lipid-core nanocapsules and in vivo genotoxicity study.

Lucas Almeida Rigo, Viviane Frescura, Luana Fiel, Karine Coradini, Aline Ferreira Ourique, Tatiana Emanuelli, Andréia Quatrin, Solange Tedesco, Cristiane B da Silva, Silvia Staniçuaski Guterres, Adriana Raffin Pohlmann, Ruy Carlos Ruver Beck

Index: Pharm. Dev. Technol. 19(7) , 789-98, (2014)

Full Text: HTML

Abstract

The use of rice bran (RB), soybean (SB) or sunflower seed (SF) oils to prepare lipid-core nanocapsules (LNCs) as controlled drug delivery systems was investigated. LNCs were prepared by interfacial deposition using the preformed polymer method. All formulations showed negative zeta potential and adequate nanotechnological characteristics (particle size 220-230  nm, polydispersity index < 0.20). The environmental safety was evaluated through an in vivo protocol (Allium cepa test) and LNCs containing RB, SB or SF oils did not present genotoxic potential. Clobetasol propionate (CP) was selected as a model drug to evaluate the influence of the type of vegetable oil on the control of the drug release from LNCs. Biphasic drug release profiles were observed for all formulations. After 168  h, the concentration of drug released from the formulation containing SF oil was lower (0.36  mg/mL) than from formulations containing SB (0.40  mg/mL) or RB oil (0.45  mg/mL). Good correlations between the consistency indices for the LNC cores and the burst and sustained drug release rate constants were obtained. Therefore, the type of the vegetal oil was shown as an important factor governing the control of drug release from LNCs.


Related Compounds

Related Articles:

Curcumin relieves TPA-induced Th1 inflammation in K14-VEGF transgenic mice.

2015-04-01

[Int. Immunopharmacol. 25(2) , 235-41, (2015)]

Topical steroids for chronic wounds displaying abnormal inflammation.

2013-05-01

[Ann. R. Coll. Surg. Engl. 95(4) , 291-6, (2013)]

Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.

2012-11-01

[Journal. of. Drugs in. Dermatology. 11(11) , 1348-54, (2012)]

Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.

2012-02-01

[Cutis. 89(2) , 89-94, (2012)]

Beefy red plaques in the perianal region.

2014-04-01

[JAMA Dermatol. 150(4) , 447-8, (2014)]

More Articles...